The comparison of automated silver in situ hybridization and fluorescence in situ hybridization for evaluating HER2 gene amplification in breast carcinoma

Journal of Breast Cancer

Volumn 12, Issue 4, 2009, Pages 295-301

  Kim, Tae Jung ^a   Kim, Tae Eun ^a   Jung, Eun Sun ^a   Yim, Hyeon Woo ^a   Song, Byung Joo ^a   Jung, Sang Seol ^a   Lee, Ahwon ^a   Choi, Yeong Jin ^a   Lee, Kyo Young ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Breast neoplasms; Fluorescence in situ hybridization; Immunohistochemistry; Silver in situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MICROSCOPY; PATHOLOGIST; SILVER ENHANCED IN SITU HYBRIDIZATION;

EID: 74849102635     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2009.12.4.295     Document Type: Article

References (17)

1. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-6.
2. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999;112:S53-67.
3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
4. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999;26:71-7.
5. Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:6598-607.
6. Lewis F, Jackson P, Lane S, Coast G, Hanby AM. Testing for HER2 in breast cancer. Histopathology 2004;45:207-17.
7. Dietel M, Ellis IO, Höfler H, Kreipe H, Moch H, Dankof A, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007;451:19-25.
8. Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 2009;54:248-53.
9. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
10. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
11. Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808.
12. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8.
13. Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6:240-6.
14. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-21.
15. Arnould L, Arveux P, Couturier J, Gelly-Marty M, Loustalot C, Ettore F, et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007;13:6404-9.
16. Carbone A, Botti G, Gloghini A, Simone G, Truini M, Curcio MP, et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn 2008;10:527-36.
17. Itoh H, Kato N, Serizawa A, Itoh T, Umemura S, Osamura RT. HER2 rabbit monoclonal antibody 4B5 and silver SISH: high performance in surgical pathology for appropriate patient care. Mod Pathol 2009;22:205.